Eris insulin glargine
Insulin glargine biosimilar developed by Eris Lifesciences. Reference product Lantus.
About Eris insulin glargine
Eris Lifesciences and its subsidiary Eris Bionxt received four Indian permissions for insulin glargine between December 2025 and June 2026, covering cartridges, vials of three sizes and a pen. Eris entered biosimilars recently and has moved quickly across the insulin range.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Eris insulin glargine holds an approval, these are the other insulin glargine biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 9 | Biocon Biologics (Semglee), Cipla (Cipla insulin glargine), Eli Lilly (Rezvoglar / Abasaglar), Genesys Biologics (Genesys insulin glargine), LG Chem (LG Life Sciences insulin glargine), Lupin (Lupin insulin glargine), M.J. Biopharm (M.J. Biopharm insulin glargine), Regenix (Regenix insulin glargine), Wockhardt (Wockhardt insulin glargine) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Eris Lifesciences: Eris human insulin.
Chronology
- CDSCODec 2025CDSCO permission granted
Sources
Planning insulin glargine biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant